Filter
735
Text search:
veterinary
Featured
54
152
Language
Document type
252
196
142
58
34
20
11
8
6
4
3
1
Countries / Regions
35
29
27
20
16
15
15
14
14
14
13
11
11
10
10
10
9
9
8
7
6
6
6
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
233
35
35
24
18
7
1
Toolboxes
190
87
61
53
46
33
22
17
15
13
13
9
6
5
5
4
4
3
2
2
2
1
1
1
1
The report focuses on antibacterial resistance (ABR) in common bacterial pathogens. There is a major gap in knowledge about the magnitude of this problem. Antimicrobial resistance (AMR) threatens the effective revention and treatment of an ever-increasing range of infections caused by bacteria, para
...
Epidemiologisches Bulletin Nr.2 /2016, S.16
WHO Technical Report Series, No. 908, 2003, Annex 9. This guide is intended for those involved in the storage, transportation and distribution of pharmaceuticals. It describes the special measures considered appropriate for the storage and transportation of pharmaceuticals.
Clinician Outreach and Communication Activity (COCA) Call
April 12, 2016
Global Action Plan on Antimicrobial Resistance
recommended
The goal of the draft global action plan is to ensure, for as long as possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them.
A series of tools and templates have been developed by WHO, FAO and OIE to accompany the manual for developing national action plans on antimicrobial resistance
National Plague Control Guidelines
recommended
Accessed Oktober 18, 2017
Antimicrobial resistance (AMR) is a multifaceted, international public health problem, which poses a direct threat to the safety of the population of South Africa. A national response is required to complement the development of a global plan, as articulated in the WHO’s draft resolution EB134/37
...
Document No. : FDA/SMC/CTD/GL-CCT/2013/01
